Background: Moxifloxacin is a second-line anti-TB drug that is useful in the treatment of drug-resistant TB. However, little is known about its target site pharmacokinetics. Lower drug concentrations at the infection site (i.e. in severe lung lesions including cavitary lesions) may lead to development and amplification of drug resistance. Improved knowledge regarding tissue penetration of anti-TB drugs will help guide drug development and optimize drug dosing. Methods: Patients with culture-confirmed drug-resistant pulmonary TB scheduled to undergo adjunctive surgical lung resection were enrolled in Tbilisi, Georgia. Five serum samples per patient were collected at different timepoints including at the time of surgical resection (approximately at Tmax). Microdialysis was performed in the ex vivo tissue immediately after resection. Non-compartmental analysis was performed and a tissue/serum concentration ratio was calculated. Results: Among the seven patients enrolled, the median moxifloxacin dose given was 7.7 mg/kg, the median age was 25.2 years, 57% were male and the median creatinine clearance was 95.4 mL/min. Most patients (71%) had suboptimal steady-state serum Cmax (total drug) concentrations. The median free moxifloxacin serum concentration at time of surgical resection was 1.23 μg/mL (range = 0.12-1.80) and the median free lung tissue concentration was 3.37 μg/mL (range = 0.81-5.76). The median free-tissue/free-serum concentration ratio was 3.20 (range = 0.66-28.08). Conclusions: Moxifloxacin showed excellent penetration into diseased lung tissue (including cavitary lesions) among patients with pulmonary TB. Moxifloxacin lung tissue concentrations were higher than those seen in serum. Our findings highlight the importance of moxifloxacin in the treatment of MDR-TB and potentially any patient with pulmonary TB and severe lung lesions.
Background: Moxifloxacin is a second-line anti-TB drug that is useful in the treatment of drug-resistant TB. However, little is known about its target site pharmacokinetics. Lower drug concentrations at the infection site (i.e. in severe lung lesions including cavitary lesions) may lead to development and amplification of drug resistance. Improved knowledge regarding tissue penetration of anti-TB drugs will help guide drug development and optimize drug dosing. Methods:Patients with culture-confirmed drug-resistant pulmonary TB scheduled to undergo adjunctive surgical lung resection were enrolled in Tbilisi, Georgia. Five serum samples per patient were collected at different timepoints including at the time of surgical resection (approximately at Tmax). Microdialysis was performed in the ex vivo tissue immediately after resection. Non-compartmental analysis was performed and a tissue/serum concentration ratio was calculated. Results: Among the seven patients enrolled, the median moxifloxacin dose given was 7.7 mg/kg, the median age was 25.2 years, 57% were male and the median creatinine clearance was 95.4 mL/min. Most patients (71%) had suboptimal steady-state serum Cmax (total drug) concentrations. The median free moxifloxacin serum concentration at time of surgical resection was 1.23 μg/mL (range = 0.12-1.80) and the median free lung tissue concentration was 3.37 μg/mL (range = 0.81-5.76). The median free-tissue/free-serum concentration ratio was 3.20 (range = 0.66-28.08). Conclusions: Moxifloxacin showed excellent penetration into diseased lung tissue (including cavitary lesions) among patients with pulmonary TB. Moxifloxacin lung tissue concentrations were higher than those seen in serum. Our findings highlight the importance of moxifloxacin in the treatment of MDR-TB and potentially any patient with pulmonary TB and severe lung lesions.
Authors: Russell R Kempker; Aline B Barth; Sergo Vashakidze; Ketino Nikolaishvili; Irina Sabulua; Nestani Tukvadze; Nino Bablishvili; Shota Gogishvili; Ravi Shankar P Singh; Jeannette Guarner; Hartmut Derendorf; Charles A Peloquin; Henry M Blumberg Journal: Antimicrob Agents Chemother Date: 2015-03-16 Impact factor: 5.191
Authors: Tawanda Gumbo; Arnold Louie; Mark R Deziel; Linda M Parsons; Max Salfinger; George L Drusano Journal: J Infect Dis Date: 2004-09-24 Impact factor: 5.226
Authors: Charles A Peloquin; David Jamil Hadad; Lucilia Pereira Dutra Molino; Moises Palaci; W Henry Boom; Reynaldo Dietze; John L Johnson Journal: Antimicrob Agents Chemother Date: 2007-12-10 Impact factor: 5.191
Authors: D Breilh; J Jougon; S Djabarouti; J B Gordien; F Xuereb; J F Velly; P Arvis; V Landreau; M C Saux Journal: J Chemother Date: 2003-12 Impact factor: 1.714
Authors: Suresh B Lakshminarayana; Tan Bee Huat; Paul C Ho; Ujjini H Manjunatha; Véronique Dartois; Thomas Dick; Srinivasa P S Rao Journal: J Antimicrob Chemother Date: 2014-11-11 Impact factor: 5.758
Authors: Christian Lienhardt; Knut Lönnroth; Dick Menzies; Manica Balasegaram; Jeremiah Chakaya; Frank Cobelens; Jennifer Cohn; Claudia M Denkinger; Thomas G Evans; Gunilla Källenius; Gilla Kaplan; Ajay M V Kumar; Line Matthiessen; Charles S Mgone; Valerie Mizrahi; Ya-Diul Mukadi; Viet Nhung Nguyen; Anders Nordström; Christine F Sizemore; Melvin Spigelman; S Bertel Squire; Soumya Swaminathan; Paul D Van Helden; Alimuddin Zumla; Karin Weyer; Diana Weil; Mario Raviglione Journal: PLoS Med Date: 2016-03-02 Impact factor: 11.069
Authors: Landry Blanc; Isaac B Daudelin; Brendan K Podell; Pei-Yu Chen; Matthew Zimmerman; Amanda J Martinot; Rada M Savic; Brendan Prideaux; Véronique Dartois Journal: Elife Date: 2018-11-14 Impact factor: 8.140
Authors: Mohammad H Al-Shaer; Wael A Alghamdi; Abdullah Alsultan; Guohua An; Shahriar Ahmed; Yosra Alkabab; Sayera Banu; Ketevan Barbakadze; Eric Houpt; Maia Kipiani; Lali Mikiashvili; J Peter Cegielski; Russell R Kempker; Scott K Heysell; Charles A Peloquin Journal: Antimicrob Agents Chemother Date: 2019-06-24 Impact factor: 5.191
Authors: Natasha Strydom; Sneha V Gupta; William S Fox; Laura E Via; Hyeeun Bang; Myungsun Lee; Seokyong Eum; TaeSun Shim; Clifton E Barry; Matthew Zimmerman; Véronique Dartois; Radojka M Savic Journal: PLoS Med Date: 2019-04-02 Impact factor: 11.069